» Articles » PMID: 34425846

Cardiac Amyloidosis Screening Using a Relative Apical Sparing Pattern in Patients with Left Ventricular Hypertrophy

Overview
Publisher Biomed Central
Date 2021 Aug 24
PMID 34425846
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cardiac amyloidosis (CA) mimics left ventricular hypertrophy (LVH). It is treatable, but its prognosis is poor. A simple screening tool for CA would be valuable. CA is more precisely diagnosed with echocardiographic deformation parameters (e.g., relative apical sparing pattern [RASP]) than with conventional parameters. We aimed to 1) investigate incremental benefits of echocardiographic deformation parameters over established parameters for CA screening; 2) determine the resultant risk score for CA screening; and 3) externally validate the score in LVH patients.

Methods: We retrospectively studied 295 consecutive non-ischemic LVH patients who underwent detailed diagnostic tests. CA was diagnosed with biopsy or Tc-PYP scintigraphy. The base model comprised age (≥65 years [men], ≥70 years [women]), low voltage on the electrocardiogram, and posterior wall thickness ≥ 14 mm in reference to the literature. The incremental benefit of each binarized echocardiographic parameter over the base model was assessed using receiver operating characteristic curve analysis and comparisons of the area under the curve (AUC).

Results: Fifty-four (18%) patients had CA. RASP showed the most incremental benefit for CA screening over the base model. After conducting multiple logistic regression analysis for CA screening using four variables (RASP and base model components), a score was determined (range, 0-4 points). The score demonstrated adequate discrimination ability for CA (AUC = 0.86). This result was confirmed in another validation cohort (178 patients, AUC = 0.88).

Conclusions: We developed a score incorporating RASP for CA screening. This score is potentially useful in the risk stratification and management of LVH patients.

Citing Articles

Novel electrocardiographic criteria may render possible the more accurate recognition of cardiac amyloidosis.

Vereckei A, Katona G, Szenasi G, Vidacs L, Foldeak D, Takacs H ESC Heart Fail. 2024; 11(2):1030-1038.

PMID: 38243379 PMC: 10966222. DOI: 10.1002/ehf2.14655.


Advance of echocardiography in cardiac amyloidosis.

Liang S, Liu Z, Li Q, He W, Huang H Heart Fail Rev. 2023; 28(6):1345-1356.

PMID: 37558934 PMC: 10575814. DOI: 10.1007/s10741-023-10332-3.


Cardiac "hypertrophy" phenotyping: differentiating aetiologies with increased left ventricular wall thickness on echocardiography.

Ferkh A, Tjahjadi C, Stefani L, Geenty P, Byth K, De Silva K Front Cardiovasc Med. 2023; 10:1183485.

PMID: 37465456 PMC: 10351962. DOI: 10.3389/fcvm.2023.1183485.


How Often Does Apical Sparing of Longitudinal Strain Indicate the Presence of Cardiac Amyloidosis?.

Wali E, Gruca M, Singulane C, Cotella J, Guile B, Johnson R Am J Cardiol. 2023; 202:12-16.

PMID: 37413701 PMC: 11529785. DOI: 10.1016/j.amjcard.2023.06.022.

References
1.
Gillmore J, Maurer M, Falk R, Merlini G, Damy T, Dispenzieri A . Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016; 133(24):2404-12. DOI: 10.1161/CIRCULATIONAHA.116.021612. View

2.
Saito M, Imai M, Wake D, Higaki R, Nakao Y, Sumimoto T . Semiquantitative assessment of the relative apical sparing pattern of longitudinal strain for cardiac amyloidosis identification. Echocardiography. 2020; 37(9):1422-1429. DOI: 10.1111/echo.14833. View

3.
de Gregorio C, Dattilo G, Casale M, Terrizzi A, Donato R, Di Bella G . Left Atrial Morphology, Size and Function in Patients With Transthyretin Cardiac Amyloidosis and Primary Hypertrophic Cardiomyopathy - Comparative Strain Imaging Study. Circ J. 2016; 80(8):1830-7. DOI: 10.1253/circj.CJ-16-0364. View

4.
Dorbala S, Cuddy S, Falk R . How to Image Cardiac Amyloidosis: A Practical Approach. JACC Cardiovasc Imaging. 2019; 13(6):1368-1383. PMC: 7148180. DOI: 10.1016/j.jcmg.2019.07.015. View

5.
Ruberg F, Grogan M, Hanna M, Kelly J, Maurer M . Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019; 73(22):2872-2891. PMC: 6724183. DOI: 10.1016/j.jacc.2019.04.003. View